Buffington Mohr McNeal increased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 14.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 7,545 shares of the medical instruments supplier’s stock after buying an additional 930 shares during the period. Buffington Mohr McNeal’s holdings in C.R. Bard were worth $1,875,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rothschild Asset Management Inc. boosted its position in shares of C.R. Bard by 6.3% in the third quarter. Rothschild Asset Management Inc. now owns 3,724 shares of the medical instruments supplier’s stock valued at $835,000 after buying an additional 220 shares during the last quarter. APG Asset Management N.V. boosted its position in shares of C.R. Bard by 138.0% in the third quarter. APG Asset Management N.V. now owns 592,362 shares of the medical instruments supplier’s stock valued at $132,855,000 after buying an additional 343,449 shares during the last quarter. Strategy Asset Managers LLC boosted its position in shares of C.R. Bard by 184.2% in the third quarter. Strategy Asset Managers LLC now owns 16,533 shares of the medical instruments supplier’s stock valued at $3,708,000 after buying an additional 10,716 shares during the last quarter. Cornerstone Wealth Management LLC bought a new position in shares of C.R. Bard during the third quarter valued at about $308,000. Finally, Huntington National Bank boosted its position in shares of C.R. Bard by 448,466.7% in the third quarter. Huntington National Bank now owns 13,457 shares of the medical instruments supplier’s stock valued at $3,017,000 after buying an additional 13,454 shares during the last quarter. 88.32% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard, Inc. (NYSE BCR) opened at 313.56 on Friday. The firm has a 50-day moving average price of $309.48 and a 200-day moving average price of $257.26. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $315.29. The company has a market capitalization of $22.71 billion, a price-to-earnings ratio of 39.91 and a beta of 0.64.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The company had revenue of $938.80 million for the quarter, compared to analysts’ expectations of $916.15 million. During the same period in the previous year, the firm posted $2.34 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Analysts anticipate that C.R. Bard, Inc. will post $11.78 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be paid a dividend of $0.26 per share. The ex-dividend date is Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s payout ratio is currently 13.21%.

TRADEMARK VIOLATION WARNING: “Buffington Mohr McNeal Boosts Position in C.R. Bard, Inc. (BCR)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/06/17/c-r-bard-inc-bcr-stake-boosted-by-buffington-mohr-mcneal-updated-updated-updated.html.

Several research analysts have weighed in on the company. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research report on Tuesday. Raymond James Financial, Inc. reissued a “market perform” rating and issued a $265.00 price objective on shares of C.R. Bard in a research report on Tuesday, April 25th. Cowen and Company boosted their price objective on C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research report on Monday, April 24th. Wells Fargo & Company cut C.R. Bard from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 25th. Finally, BMO Capital Markets cut C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research report on Tuesday, April 25th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $265.62.

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the sale, the vice president now directly owns 10,139 shares of the company’s stock, valued at $3,082,256. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.